eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2018-06-25 11 2 1119 1126 10.13005/bpj/1472 21172 article Anjali Devi S. Bettadapura 1 Vijay K. Munivenkatappa 2 Subba Rao V. Madhunapantula 1,3 Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru - 570015, Karnataka, India. Department of Oncosurgery, Bharath Hospital and Institute of Oncology, Mysuru - 570 017, Karnataka, India. Special Interest Group in Cancer Biology and Cancer Stem Cells (SIG-CBCSC), JSS Academy of Higher Education and Research, Mysuru - 570015, Karnataka, India. Carcinoma of cervix is one of the major health concerns among women. Although Effective preventive methods are available to protect individuals from getting cervical cancer, the incidence and mortality rates due to this disease are increasing at alarming rates.  In addition, currently, no potent treatment strategies exist to treat advanced cervical cancers.  Therefore, identification of key biomarkers that indicate the severity  and drug resistance of cervical cancers is of high importance. Comparative analysis of transcriptome of tumor- and normal tissue is one way of determining the deregulated genes, which serve as biomarkers.  Hence, in this study the transcriptome of malignant cervical cancer tissues was compared with adjacent non-tumor tissue and genes that are at least 2-fold high were selected.  Among various selected genes, Bone gamma carboxyglutamic acid containing protein (BGLAP, commonly known as Osteocalcin) was found consistently high in all the tumor tissue compared to adjacent non-tumor tissue.  Hence, BGLAP could be a potential biomarker for identifying malignant cervical cancer tumors. https://biomedpharmajournal.org/vol11no2/transcriptome-analysis-identified-elevated-expression-of-bone-gamma-carboxyglutamic-acid-containing-protein-bglap-in-human-cervical-cancer-tissues/ BGLAP Carboxyglutamic Effective